Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; magnesium stearate; povidone; purified talc; hypromellose; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 146.32 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 73.16 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; citric acid monohydrate; magnesium stearate; povidone; purified talc; alginic acid; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desvenlafaxine benzoate, quantity: 146.32 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desvenlafaxine benzoate, quantity: 73.16 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: magnesium stearate; purified talc; povidone; hypromellose; citric acid monohydrate; microcrystalline cellulose; alginic acid; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: purified talc; microcrystalline cellulose; alginic acid; magnesium stearate; hypromellose; povidone; citric acid monohydrate; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desvenlafaxine, quantity: 100 mg (equivalent: desvenlafaxine succinate monohydrate, qty 151.7 mg) - tablet, modified release - excipient ingredients: polyvinyl alcohol; hypromellose; iron oxide red; microcrystalline cellulose; magnesium stearate; titanium dioxide; silicon dioxide; macrogol 8000; purified talc - desvenlafaxine mr apotex modified release tablets are indicated for the treatment of major depressive disorder, including the prevention of relapse.,it is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine -